Journal of Cancer Research and Clinical Oncology

, Volume 140, Issue 7, pp 1067–1073 | Cite as

A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus

  • Hou-bao Huang
  • Shu-chuan Jiang
  • Jie Han
  • Qing-shui Cheng
  • Chang-bin Dong
  • Cai-ming Pan
Review - Cancer Research



A grow body of studies has evaluated the risk of development of urological cancer in systemic lupus erythematosus (SLE) with inconclusive results. To clarify the association, a meta-analysis approach was performed to assess the published evidence on urological cancers and SLE.


Relevant English electronic databases were systematic searched for published studies characterizing the risk of developing urological cancer as a result of SLE. Standardized incidence rate (SIR) with its 95 % confidence interval (CI) of each study was combined using a fixed-/random-effect model in STATA software.


A total of 12 papers including 68366 SLE patients were suitable for meta-analysis. Of these, 9 reported the SIR for prostate cancer, 7 for bladder cancer and 6 for kidney cancer. Summary SIRs were 0.77 (95 % CI 0.69–0.87, P < 0.001); 1.75 (95 % CI 0.94–3.23, P = 0.075) and 2.29 (95 % CI 1.25–4.18, P = 0.007), respectively. Significant heterogeneity was noticed in subgroups of bladder and kidney cancer. No obvious publication bias was detected.


Findings from this meta-analysis indicate that SLE is associated with a decreased risk of prostate cancer and an increased risk of kidney cancer.


Urological cancer Systemic lupus erythematosus Meta-analysis SIR 


Conflict of interest



  1. Abu-Shakra M, Gladman DD, Urowitz MB (1996) Malignancy in systemic lupus erythematosus. Arthritis Rheum 39(6):1050–1054PubMedCrossRefGoogle Scholar
  2. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101PubMedCrossRefGoogle Scholar
  3. Bernatsky S, Ramsey-Goldman R, Foulkes WD, Gordon C, Clarke AE (2011) Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer 104(9):1478–1481PubMedCentralPubMedCrossRefGoogle Scholar
  4. Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M et al (2013) Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 42:130–135PubMedCentralPubMedCrossRefGoogle Scholar
  5. Björnådal L, Löfström B, Yin L, Lundberg IE, Ekbom A (2002) Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31(2):66–71PubMedCrossRefGoogle Scholar
  6. Cammarata RJ, Rodnan GP, Jensen WN (1963) Systemic rheumatic disease and malignant lymphoma. Arch Intern Med 111:330PubMedCrossRefGoogle Scholar
  7. Chen YJ, Chang YT, Wang CB, Wu CY (2010) Malignancy in systemic lupus erythematosus: a nationwide cohort study in Taiwan. Am J Med 123(12):1150.e1-6PubMedGoogle Scholar
  8. Chun BC, Bae SC (2005) Mortality and cancer incidence in Korean patients with systemic lupus erythematosus: results from the Hanyang lupus cohort in Seoul. Korea. Lupus. 14(8):635–638CrossRefGoogle Scholar
  9. Cibere J, Sibley J, Haga M (2001) Systemic lupus erythematosus and the risk of malignancy. Lupus. 10(6):394–400PubMedCrossRefGoogle Scholar
  10. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  11. Dreyer L, Faurschou M, Mogensen M, Jacobsen S (2011) High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow up study in a Danish cohort. Arthritis Rheum 63(10):3032–3037PubMedCrossRefGoogle Scholar
  12. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCentralPubMedCrossRefGoogle Scholar
  13. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558PubMedCrossRefGoogle Scholar
  14. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRefGoogle Scholar
  15. Kang KY, Kim HO, Yoon HS, Lee J, Lee WC, Ko HJ et al (2010) Incidence of cancer among female patients with systemic lupus erythematosus in Korea. Clin Rheumatol 29(4):381–388PubMedCrossRefGoogle Scholar
  16. Kinlen LJ (1992) Malignancy in autoimmune diseases. J Autoimmun 5(Suppl A):363–371PubMedCrossRefGoogle Scholar
  17. Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799PubMedCrossRefGoogle Scholar
  18. Liu H, Ding Q, Yang K, Zhang T, Li G, Wu G (2011) Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford) 50(2):343–348CrossRefGoogle Scholar
  19. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  20. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH (1997) Non-Hodgkin’s lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40(4):761–768PubMedCrossRefGoogle Scholar
  21. Mok CC, Lau CS (2000) Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus 9(4):252–257PubMedCrossRefGoogle Scholar
  22. Mononen N, Schleutker J (2009) Polymorphisms in genes involved in androgen pathways as risk factors for prostate cancer. J Urol 181(4):1541–1549PubMedCrossRefGoogle Scholar
  23. Ni J, Qiu LJ, Hu LF, Cen H, Zhang M, Wen PF et al (2014) Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: evidence from a meta-analysis. Lupus. doi: 10.1177/0961203313520060 PubMedGoogle Scholar
  24. Nived O, Bengtsson A, Jönsen A, Sturfelt G, Olsson H (2001) Malignancies during follow-up in an epidemiologically defined systemic lupus erythematosus inception cohort in southern Sweden. Lupus 10(7):500–504PubMedCrossRefGoogle Scholar
  25. Parikh-Patel A, White RH, Allen M, Cress R (2008) Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California. Cancer Causes Control 19(8):887–894PubMedCrossRefGoogle Scholar
  26. Ragnarsson O, Gröndal G, Steinsson K (2003) Risk of malignancy in an unselected cohort of Icelandic patients with systemic lupus erythematosus. Lupus 12(9):687–691PubMedCrossRefGoogle Scholar
  27. Sultan SM, Ioannou Y, Isenberg DA (2000) Is there an association of malignancy with systemic lupus erythematosus? An analysis of 276 patients under long-term review. Rheumatology (Oxford) 39(10):1147–1152CrossRefGoogle Scholar
  28. Tarr T, Gyorfy B, Szekanecz E, Bhattoa HP, Zeher M, Szegedi G et al (2007) Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 1108:76–82PubMedCrossRefGoogle Scholar
  29. Zintzaras E, Voulgarelis M, Moutsopoulos HM (2005) The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165(20):2337–2344PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Hou-bao Huang
    • 1
  • Shu-chuan Jiang
    • 1
  • Jie Han
    • 1
  • Qing-shui Cheng
    • 1
  • Chang-bin Dong
    • 1
  • Cai-ming Pan
    • 1
  1. 1.Department of Urology, Yiji Shan HospitalThe First Affiliated Hospital of Wannan Medical CollegeWuhuChina

Personalised recommendations